|
May 6
|
Three-month interim report (Q1) 2025 (unaudited)
|
|
May 2
|
ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians
|
|
May 2
|
ALK enters into neffy® co-promotion agreement in the USA
|
|
Apr 23
|
ITULAZAX® tree pollen tablet approved for treatment of children in Europe
|
|
Feb 12
|
Invitation to the presentation of ALK’s annual report 2024 on Wednesday, 19 February 2025
|
|
Oct 9
|
Alk-Abello AS (AKBLF) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Upgraded Outlook
|
|
Oct 7
|
ALK Announces U.S. FDA Approval of New AccuTest™ Allergy Skin Testing Devices for Optimized Allergy Testing and Diagnosis
|
|
Jun 21
|
ALK upgrades its full-year revenue and earnings outlook
|
|
Jun 21
|
ALK provides update on regulatory process for the house dust mite allergy tablet in China
|
|
Feb 16
|
Annual General Meeting in ALK-Abelló A/S on 14 March 2024
|
|
Dec 20
|
ALK – Financial calendar for the 2024 financial year
|
|
Oct 11
|
Large Phase 3 clinical trial successfully meets primary endpoint, confirming the potential of ALK’s tree tablet in children
|